Additionally, TOP2A is a molecular target of anthracycline, and previous reports have shown that TOP2A amplified or deleted are predictive markers of anthracycline-containing adjuvant chemotherapy regimens for early breast cancer [10–13]. This evidence concerns the gene TOP2A and breast carcinoma.